Announcement & Circular
Corporate Governance
Financial Results
Presentations
IR Activities
Contact Us
Announcement & Circular
Stock Information
02186.HK
5.040 -0.080  (-1.563%)
2020/08/07 16:08
07-23
2020
Environmental, Social and Governance Report 2019
Publisher：
06-29
2020
ADJUSTMENT TO CONVERSION PRICE OF THE U.S.$300,000,000 1.50 PER CENT. CONVERTIBLE BONDS DUE 2024
Publisher：
06-29
2020
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION OF LURBINECTEDIN HAS BEEN FORMALLY ACCEPTED BY CDE
Publisher：
06-23
2020
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION OF LPM4870108 TABLETS HAS BEEN FORMALLY ACCEPTED BY CDE
Publisher：
06-18
2020
VOLUNTARY ANNOUNCEMENT - THE IND APPLICATION OF RIVASTIGMINE MULTI-DAY TRANSDERMAL PATCH (LY03013) HAS BEEN ACCEPTED BY CDE IN CHINA
Publisher：
06-11
2020
CLINICAL TRIAL APPLICATION OF HYDROCHLORIDE IRINOTECAN FLOXURUDINE LIPOSOME INJECTION (LY01616) WAS FORMALLY ACCEPTED BY CDE
Publisher：
06-09
2020
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR INITIATING CLINICAL TRIAL FOR DENOSUMAB INJECTION (LY06006/LY01011) IN THE UNITED STATES
Publisher：
06-05
2020
VOLUNTARY ANNOUNCEMENT - MARKETING REGISTRATION OF RIVASTIGMINE TRANSDERMAL PATCH APPROVED BY NMPA
Publisher：
05-21
2020
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 23 JUNE 2020
Publisher：
05-21
2020
NOTICE OF ANNUAL GENERAL MEETING
Publisher：
First
1
2
3
4
5
Last
Investors
Announcement & Circular
Corporate Governance
Financial Results
Presentations
IR Activities
Contact Us
Stock Information
02186.HK
2020/08/07 16:08
5.040
-0.080   (  -1.563%  )
Announcement & Circular
07-23
2020
Environmental, Social and Governance Report 2019
06-29
2020
ADJUSTMENT TO CONVERSION PRICE OF THE U.S.$300,000,000 1.50 PER CENT. CONVERTIBLE BONDS DUE 2024
06-29
2020
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION OF LURBINECTEDIN HAS BEEN FORMALLY ACCEPTED BY CDE
06-23
2020
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION OF LPM4870108 TABLETS HAS BEEN FORMALLY ACCEPTED BY CDE
06-18
2020
VOLUNTARY ANNOUNCEMENT - THE IND APPLICATION OF RIVASTIGMINE MULTI-DAY TRANSDERMAL PATCH (LY03013) HAS BEEN ACCEPTED BY CDE IN CHINA
06-11
2020
CLINICAL TRIAL APPLICATION OF HYDROCHLORIDE IRINOTECAN FLOXURUDINE LIPOSOME INJECTION (LY01616) WAS FORMALLY ACCEPTED BY CDE
06-09
2020
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR INITIATING CLINICAL TRIAL FOR DENOSUMAB INJECTION (LY06006/LY01011) IN THE UNITED STATES
06-05
2020
VOLUNTARY ANNOUNCEMENT - MARKETING REGISTRATION OF RIVASTIGMINE TRANSDERMAL PATCH APPROVED BY NMPA
05-21
2020
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 23 JUNE 2020
05-21
2020
NOTICE OF ANNUAL GENERAL MEETING
First
1
2
3
4
5
Last